A phase 1B, open-label, dose-escalation study of bortezomib in combination with gemcitabine (Gem) and cisplatin (Cis) in the first-line treatment of patients with advanced solid tumors: Preliminary results of a phase IB study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase 1B, open-label, dose-escalation study of bortezomib in combination with gemcitabine (Gem) and cisplatin (Cis) in the first-line treatment of patients with advanced solid tumors: Preliminary results of a phase IB study

Published:2005-06 Issue:16_suppl Volume:23 Page:2103-2103
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Voortman J.¹,Smit E. F.¹,Kuenen B. C.¹,Pinedo H. M.¹,van Groeningen C.¹,van den Eertwegh A. J.¹,Brouwer D.¹,van de Velde H.¹,Giaccone G.¹

Affiliation:

1. VU Univ Medcl Ctr, Amsterdam, The Netherlands; Janssen-Cilag, Tilburg, The Netherlands; Johnson & Johnson PRD, Beerse, Belgium

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2005.23.16_suppl.2103

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence;Expert Opinion on Therapeutic Targets;2007-11-18

2. Proteasome inhibitors and modulators of heat shock protein function;Update on Cancer Therapeutics;2006-06

3. Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report;BMC Cancer;2006-05-11

4. Targeting the ubiquitin–proteasome pathway in breast cancer therapy;Future Oncology;2006-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP